Budesonide/Formoterol (Symbicort 200/6 Turbohaler)
Is It Right for You?
A complete guide to Budesonide/Formoterol (Symbicort 200/6 Turbohaler) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Symbicort 200/6 Turbohaler?
Symbicort 200/6 Turbohaler is a combination inhaler containing budesonide 200 micrograms (an inhaled corticosteroid, ICS) and formoterol fumarate 6 micrograms (a long-acting beta-2 agonist, LABA) per delivered dose. It is used for the maintenance treatment of asthma in adults and adolescents, and as maintenance and reliever therapy (MART) in appropriate asthma patients. It is also used for the management of moderate-to-severe chronic obstructive pulmonary disease (COPD).
Budesonide suppresses airway inflammation — the underlying driver of asthma and COPD exacerbations — while formoterol provides rapid and sustained bronchodilation by relaxing airway smooth muscle. The combination of these two complementary mechanisms in a single inhaler improves patient adherence and provides superior disease control compared to either agent used alone.
Symbicort is a prescription-only medication in the UK. A clinician must assess your respiratory diagnosis, inhaler technique capability, and clinical history before prescribing.
What Conditions Is Symbicort 200/6 Turbohaler Used For?
Symbicort is indicated for:
regular maintenance treatment where a combination of ICS and LABA is appropriate; also approved for MART (Maintenance and Reliever Therapy), where a single inhaler is used for both daily maintenance dosing and as-needed relief of acute symptoms
symptomatic maintenance treatment in adults with moderate-to-severe COPD (FEV1 <70% predicted), reducing exacerbation frequency and improving exercise tolerance and quality of life
formoterol's rapid onset means Symbicort can be used as pre-exercise prophylaxis in asthma patients managed on MART
Symbicort is a controller medication. Regular daily use is required to maintain disease control. Budesonide treats the underlying airway inflammation; formoterol provides bronchodilation. In MART, the same inhaler also serves as the reliever — but patients on fixed maintenance dosing must use a separate fast-acting reliever inhaler (e.g., salbutamol) for acute symptoms.
How Does Symbicort Work?
Symbicort's efficacy derives from the complementary mechanisms of its two components: Budesonide is an inhaled glucocorticoid with potent local anti-inflammatory activity and minimal systemic bioavailability. It binds to intracellular glucocorticoid receptors in airway epithelial cells and immune cells, suppressing the transcription of pro-inflammatory mediators — including interleukins, TNF-α, and eosinophil-activating cytokines — that drive the chronic airway inflammation, hyperresponsiveness, and remodelling characteristic of asthma. In COPD, it reduces the frequency of exacerbations by dampening inflammatory activity in already-damaged airways. Formoterol fumarate is a selective beta-2 adrenergic agonist. It binds to beta-2 receptors on airway smooth muscle, activating adenylyl cyclase and raising intracellular cyclic AMP, which triggers smooth muscle relaxation and bronchodilation. Formoterol is notable for its rapid onset of action (comparable to salbutamol) — within 1–3 minutes — combined with a long duration of action (up to 12 hours), making it uniquely suited for both maintenance and reliever therapy. The synergy between ICS and LABA is pharmacologically significant: corticosteroids upregulate beta-2 receptor expression (maintaining LABA sensitivity) while LABAs enhance the anti-inflammatory efficacy of ICS at the cellular level.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Master your Turbohaler technique. The Turbohaler is a breath-actuated dry powder device — it requires a forceful, deep inhalation. Unlike pressurised metered-dose inhalers (pMDIs), it does not require coordination with pressing a canister. A clinician or pharmacist should demonstrate and confirm correct technique at initiation.
You may not taste or feel the dose. The Turbohaler delivers a very fine powder — absence of sensation does not mean the dose has not been inhaled.
Rinse your mouth after every use. Budesonide deposited in the oropharynx can cause oral candidiasis (thrush) and dysphonia. Rinsing and spitting (without swallowing) after each dose significantly reduces this risk.
Do not exceed 8 inhalations per day in MART. If you are regularly requiring more than 8 inhalations per day, your asthma is not adequately controlled and you must seek clinical review.
Track your reliever use. Increasing frequency of as-needed inhalations is an early warning sign of deteriorating asthma control; contact your clinician promptly
Side Effects of Symbicort 200/6 Turbohaler
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Oral candidiasis (thrush) --- white patches in the mouth or throat; largely preventable with mouth rinsing after each dose
- Dysphonia (hoarseness or voice changes) --- due to local corticosteroid deposition on the larynx
- Palpitations or mild tachycardia --- from formoterol's beta-2 agonist activity
- Tremor (fine tremor of the hands) --- beta-2 agonist effect; usually mild and transient
- Headache
- Throat irritation or mild cough on inhalation
- Paradoxical bronchospasm --- rarely, inhalation can trigger immediate worsening of bronchospasm; discontinue and use a fast-acting bronchodilator
- Severe hypokalaemia --- high-dose beta-2 agonist therapy can lower serum potassium, particularly in combination with theophylline, steroids, or diuretics; risk of cardiac arrhythmia
- Adrenal suppression --- uncommon at standard doses but possible with high-dose or prolonged ICS therapy; relevant in patients switched from oral steroids or children on prolonged treatment
- Cardiovascular effects --- tachycardia, QT prolongation, arrhythmias (at high formoterol doses or in susceptible patients)
- Hypersensitivity reactions --- angioedema, urticaria, anaphylaxis; rare
In MART, patients using more than 8 inhalations daily require urgent medical review. Increasing reliever use indicates loss of asthma control and risk of a life-threatening exacerbation. Symbicort is not suitable for managing acute severe asthma — patients should have a written asthma action plan and access to emergency care.
Drug Interactions
Symbicort may interact with other medications, including beta-blockers, QT-prolonging drugs, loop and thiazide diuretics, theophylline, and potent CYP3A4 inhibitors. Always inform your clinician about all medications you are taking.
cardioselective and non-selective beta-blockers antagonise the bronchodilatory effect of formoterol; may precipitate severe bronchospasm in asthma patients; avoid non-selective beta-blockers; use cardioselective agents with caution.
formoterol prolongs the QT interval; concomitant use of other QT-prolonging drugs (certain antipsychotics, antiarrhythmics, macrolide antibiotics) increases the risk of serious arrhythmia; review all medications.
may potentiate formoterol-induced hypokalaemia; monitor serum potassium.
additive risk of hypokalaemia and cardiac arrhythmia with high-dose beta-2 agonists; monitor closely.
Important Warnings
Symbicort is not appropriate for treatment of acute severe asthma attacks. Patients must have access to a separate fast-acting reliever (salbutamol) for emergency use if not on MART, and must know when to seek emergency care (999 / A&E) for an acute attack.
Rinsing the mouth with water and spitting after every dose of Symbicort is the single most effective measure to prevent oral thrush and dysphonia. This should be performed consistently after every use.
Patients on high doses of inhaled corticosteroids for prolonged periods may develop clinically significant adrenal suppression. Those on high-dose ICS therapy should carry a steroid warning card and be aware of the need for steroid supplementation during physiological stress (e.g., surgery, serious illness).
Poorly controlled asthma in pregnancy poses a greater risk to mother and fetus than well-managed asthma with inhaled medication. Budesonide and formoterol are generally considered safe during pregnancy; do not stop treatment without consulting your clinician. Seek specialist review for asthma management throughout pregnancy.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Symbicort 200/6 Turbohaler FAQs
MART (Maintenance and Reliever Therapy) means using Symbicort for both your regular daily maintenance dose AND as an as-needed reliever when you have symptoms. This approach is supported by clinical evidence and is approved in adults with asthma. It is not used in COPD or in children under 18. Your clinician will advise whether MART is appropriate for you.
Yes. The Turbohaler delivers a very fine dry powder that is largely imperceptible on inhalation. Many patients experience this. Provided your technique is correct (forceful, deep inhalation), the dose is being delivered. A pharmacist or nurse can check your technique.
Budesonide is deposited in the mouth and throat during inhalation. This local corticosteroid can promote fungal (candida) overgrowth, causing oral thrush, and can cause voice hoarseness. Rinsing with water and spitting after every dose prevents this effectively.
If you are on MART, you can use Symbicort as your reliever during acute symptoms (up to the daily maximum). If you are on fixed maintenance dosing, you should use a separate salbutamol inhaler for acute relief. Neither approach replaces emergency care for severe attacks — if your symptoms are not responding, call 999.
At standard prescribed doses, clinically significant adrenal suppression is unlikely. However, patients on high doses or with prolonged ICS exposure can develop some degree of suppression. Your clinician will review your total ICS dose and advise if a steroid card is required.